Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rocatinlimab drug-drug interaction study in atopic dermatitis
NCT05891119Phase 1Completed
- Sponsor
- Amgen
- Start
- Jun 2023
- Primary completion
- Aug 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of rocatinlimab in atopic dermatitis (AD), sponsored by Amgen. Primary endpoints: Maximum Observed Serum Concentration of CYP450 Substrate at Day 120, Area Under the Serum Concentration-Time Curve from Time Zero to Time of Last Quantifiable Concentration of CYP450 Substrate at Day 120 and 1 more. Started Jun 2023; status: completed.
02
Drugs
rocatinlimab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT05891119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05891119.